Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate

Rozin, Alexander; Schapira, D.; Balbir‐Gurman, Alexandra; Braun‐Moscovici, Yolanda; Markovits, Doron; Militianu, Daniela; Nahir, M.

doi:10.1136/ard.61.8.756

Cited by 34 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hay que reseñar que nuestro estudio no evaluaba el cumplimiento del tratamiento en la población estudiada, pero diversos autores proponen el cambio a la forma inyectable para pacientes con bajo cumplimiento y/o efectos gastrointestinales del metotrexato oral [11,14,15,[23][24][25][26][27][28]. Estos trabajos ponen de relieve una mayor probabilidad de eficacia con metotrexato inyectable y un mejor perfil de efectos adversos gastrointestinales que con metotrexato oral.…”

Section: Discussionunclassified

Condicionantes demográficos y clínicos para la elección inicial de la vía de administración de metotrexato y motivos para un posterior cambio de vía (Estudio MOTICAR)

Blanco¹

2015

acta reuma

View full text Add to dashboard Cite

Section: Discussionunclassified

Condicionantes demográficos y clínicos para la elección inicial de la vía de administración de metotrexato y motivos para un posterior cambio de vía (Estudio MOTICAR)

Blanco¹

2015

acta reuma

View full text Add to dashboard Cite

“…Indeed, some clinical studies have also proposed to use subcutaneous MTX as a reasonable alternative and to switch from the oral to the parenteral route of administration [Jundt et al 1993]. In general, food intake has no major effect on the bioavailability of low dose MTX in patients with RA [Rozin et al 2002]. However, although the peak concentration of MTX is not reduced by the intake of food, the time to reach the highest concentration seems slightly longer.…”

Section: Radiographic Progressionmentioning

confidence: 99%

Methotrexate: Optimizing the Efficacy in Rheumatoid Arthritis

Braun¹

2011

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Methotrexate (MTX) is currently the most frequently used drugs in the treatment of rheumatoid arthritis (RA). The drug had been synthesized in 1948 and first tests to treat patients with psoriasis and RA were published in 1951. However, until the 1980s there was only limited use of MTX in the treatment of RA. Since the 1990s MTX is the disease-modifying antirheumatic drug (DMARD) of first choice for the treatment of RA in most countries worldwide. By definition, DMARDs in RA are those compounds for which an inhibiting effect on radiographic progression has been demonstrated. Several combinations of DMARDs have been tested, most commonly with MTX as the anchor drug. Regarding the route of administration of MTX there is some evidence that the parenteral route, most often performed subcutaneously, has some additional benefits over the oral route. In MTX monotherapy, dosages up to 30 mg/ week are now used. There are now three main combinations that are playing an important role: MTX þ sulfasalazine (SSZ) þ hydroxychloroquine, MTX þ leflunomide (LEF), and MTX þ biologics such as antitumour necrosis factor (anti-TNF) and other new compounds which block the interleukin 6 (IL6) receptor or T-cell activation and delete B cells. Regarding clinical efficacy, MTX monotherapy has performed almost similarly well in comparison with biologic monotherapy, both usually combined with glucocorticoids. However, structural damage is usually inhibited to a significantly greater degree with the biologics. The combination of MTX with biologics has proven superior to either agent alone in all aspects. Current strategic regimens which concentrate on systematic ways to bring patients into remission all include MTX as first choice.

show abstract

“…Доказаны более высокие эффектив-ность, переносимость [135][136][137][138][139][140][141][142][143][144][145][146][147][148] и биодоступность [149] подкожной лекарственной формы МТ по сравнению с таб-летированной формой препарата; у пациентов с недоста-точной эффективностью или плохой переносимостью таб-летированного МТ применение его подкожной формы по-зволяет снизить потребность в назначении ГИБП [150]. Комментарий.…”

unclassified

Project: Recommendations on Treatment of Rheumatoid Arthritis Developed by All-Russian Public Organization «association of Rheumatologists of Russia» – 2014 (Part 1)

Насонов¹,

Mazurov²,

Каратеев³

et al. 2015

rsp

View full text Add to dashboard Cite

Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate

Cited by 34 publications

References 15 publications

Condicionantes demográficos y clínicos para la elección inicial de la vía de administración de metotrexato y motivos para un posterior cambio de vía (Estudio MOTICAR)

Condicionantes demográficos y clínicos para la elección inicial de la vía de administración de metotrexato y motivos para un posterior cambio de vía (Estudio MOTICAR)

Methotrexate: Optimizing the Efficacy in Rheumatoid Arthritis

Project: Recommendations on Treatment of Rheumatoid Arthritis Developed by All-Russian Public Organization «association of Rheumatologists of Russia» – 2014 (Part 1)

Contact Info

Product

Resources

About